Improving patient recruitment and retention in clinical trials: Travel is a significant barrier for trial participants. Moving the clinical site to the home can substantially improve retention rates.
ICH E6(R3) Readiness: Japan is preparing for the shift to updated global standards. These rules require a Quality by Design approach, emphasizing proactive quality management.
Unbroken Chain of Custody: Maintaining the stability of unapproved medicines outside a clinical setting requires precise temperature control, IoT sensors, and specialized delivery services.
Scalable Compliance: Successful trials in Japan require deep expertise in navigating the Ministry of Health, Labour and Welfare (MHLW) regulations and reaching participants across diverse locations.
The clinical trial landscape is undergoing a significant transformation. As interest in patient-centered healthcare continues to grow, pharmaceutical companies and CROs are under increasing pressure to design studies that are more accessible to diverse patient populations. One of the most promising approaches is the adoption of Decentralized Clinical Trials (DCTs).
In a DCT model, patients are not always required to visit a clinical trial site in person. Instead, trials are designed to allow participation from home or local healthcare facilities, offering greater flexibility and convenience. A critical enabler of this new trial model is Direct-to-Patient (DtP) logistics.
Beyond simply delivering investigational medicinal products (IMPs) to patients' homes, DtP logistics involves managing the entire clinical trial supply chain, including quality assurance, regulatory compliance, and biological sample collection. As DCT adoption grows, ensuring the safe and compliant movement of trial materials has become more important than ever.
Patient recruitment and retention have long been among the greatest challenges in clinical research.
Data show that participants enrolled in Phase I oncology trials travel an average of approximately 70 kilometers (43 miles) to participate. Regular visits to clinical trial sites can create a significant burden not only for patients but also for family members and caregivers, potentially leading to participant dropout.
Traditional trial models also tend to concentrate recruitment around large urban hospitals, limiting participation opportunities for individuals living in rural areas or those with mobility constraints.
DCTs aim to remove these barriers and create a more patient-friendly clinical trial experience. By combining telemedicine, digital health technologies, and DtP logistics, sponsors can enable patients to participate from locations that are more convenient to them.
As a result, DCTs have the potential to improve patient retention while also expanding access to broader and more diverse patient populations.
DtP logistics refers to a distribution model in which investigational medicinal products are delivered directly to patients' homes rather than being dispensed solely at clinical trial sites.
In traditional clinical trials, study drugs are transported from manufacturing facilities through storage and distribution centers before being provided to participants during site visits. Under the DtP model, with appropriate approvals and controls in place, investigational products can be safely delivered directly to trial participants.
The primary benefit of DtP logistics is its ability to reduce patient burden while maintaining trial continuity.
By reducing the number of required site visits, DtP logistics improves convenience for participants and helps mitigate disruptions caused by weather, transportation issues, or geographic distance. Furthermore, it enables sponsors to reach potential participants who may not otherwise have been able to enroll in a study.
At the same time, delivering investigational products directly to patients extends quality management activities beyond the clinical trial site, requiring a significantly higher level of logistics expertise and oversight.
Another factor accelerating the adoption of DCTs and DtP logistics is the implementation of ICH E6(R3).
ICH E6(R3) is the latest version of the internationally recognized Good Clinical Practice (GCP) guideline developed by the International Council for Harmonisation (ICH). Adopted in 2025, the updated guideline places stronger emphasis on decentralized clinical trial models, digital technologies, risk-based quality management, and Quality by Design (QbD) principles.
The new framework encourages organizations to identify and mitigate risks proactively rather than responding after problems occur.
From a logistics perspective, this means establishing systems capable of demonstrating that investigational products maintained their required quality throughout the entire distribution process.
Organizations must be able to track:
Every step of the journey must be fully traceable.
For this reason, DtP logistics should not be viewed simply as a delivery service. It has become an integral component of the overall quality assurance strategy for clinical trials.
Many investigational products used in clinical trials require strict temperature control throughout transportation and storage.
This is especially true for:
These products often require tightly controlled conditions, such as:
Even minor temperature excursions can impact product quality and efficacy. In some cases, temperature deviations may compromise the integrity of clinical trial data itself.
As a result, modern clinical supply chains increasingly rely on advanced temperature-controlled packaging combined with IoT-enabled visibility solutions.
Real-time monitoring devices continuously track:
This enables logistics providers and sponsors to detect issues early and take corrective action before product integrity is compromised.
In addition, digital records of transportation and temperature history provide valuable documentation for regulatory inspections and quality assurance reviews.
As DtP adoption continues to grow, logistics infrastructure capable of objectively verifying shipment quality will become increasingly important.
When implementing a DtP model in Japan, regulatory compliance is just as important as logistics quality.
Sponsors and logistics providers must comply with various regulations, including requirements under Japan's Pharmaceuticals and Medical Devices Act (PMD Act).
For multinational clinical trials, import procedures and customs clearance processes also play a critical role.
For example, discrepancies between import documentation and clinical trial documentation may result in customs delays or additional inspections. Such disruptions can affect patient delivery schedules and impact overall trial operations.
Furthermore, successful DtP implementation requires reliable nationwide distribution capabilities, including service coverage extending beyond major cities to rural regions and remote islands.
To operate DtP programs successfully in Japan, logistics providers must combine transportation expertise with a deep understanding of local pharmaceutical regulations and clinical trial requirements.
Security and privacy are of the utmost importance when delivering sensitive medical products to a private residence. It is imperative to ensure the medicine is handed directly to the verified participant or their legally designated representative.
Identity Verification: We perform rigorous identity checks against trial records before any package is handed over.
Point-of-Use Delivery: When required, our couriers can place the medication directly into the participant’s designated storage area or refrigerator.
Instruction Support: We confirm that the patient understands how to correctly handle the specialized packaging.
Safe Disposal: Our service includes the collection of used kits or sharp containers for proper, medical-grade destruction, closing the logistics loop securely.
A DtP trial is not complete upon delivery. It is equally important to manage the return flow of biological samples and any unused investigational products back to the central laboratory with precision.
Stability Windows: Biological samples, such as blood or urine, must be collected and returned to the laboratory within strictly defined time and temperature parameters.
Data Integrity: If a sample deviates from its required temperature range during transit, the integrity of the resulting trial data may be compromised.
Remote Reach: We utilise specialised transport solutions to reliably collect samples from participants across Japan, from major urban centres to more remote locations.
Unified Visibility: A clinical research associate in Tokyo should have access to the exact same tracking data as a sponsor in Europe, ensuring global consistency.
Direct-to-Patient logistics has transitioned from a future concept to a practical necessity. It represents a superior method for enhancing the patient experience and safeguarding the integrity of your data. DHL Health Logistics is prepared to assist you in scaling your research throughout Japan and the wider APAC region. We invite you to speak with a DHL specialist today to review your trial plan and reach your participants with confidence.
They remove the significant physical burden of travel by arranging for the delivery of investigational medicine directly to the participant's home. This makes it far more manageable for patients to adhere to the study protocol while maintaining their daily routines.
These 2026 guidelines will require sponsors to implement a Quality by Design approach. This means you must possess digital, verifiable proof that your investigational products were maintained under stable conditions throughout the entire journey to the patient.
We employ real-time IoT sensors that transmit live location and thermal data to a central dashboard. This system ensures that you receive an immediate alert if the shipment deviates from its pre-defined temperature range.
Yes, though it requires a partner with demonstrated expertise in handling the specific local medical licenses and import regulations in each country. Utilising a standardized digital platform like MyDHL+ ensures your data remains consistent and comparable across diverse markets like Japan.
Yes, our couriers follow a strict, verified delivery protocol. This procedure includes checking the participant's official identification to ensure the sensitive medication is handed over exclusively to the correct, authorized person.
Share
